www.fdanews.com/articles/81231-croatia-s-pliva-sells-proprietary-drug-in-u-s
CROATIA'S PLIVA SELLS PROPRIETARY DRUG IN U.S.
September 28, 2005
Croatian pharmaceutical concern Pliva (PLV.xq.L: Quote, Profile, Research) said on Wednesday it had sold a drug from its failed proprietary business in the U.S. for an immediate payment of $32 million and potentially more in the future. Pliva said it had made an agreement to sell VoSpire ER, a drug for the relief of bronchospasm, to a privately held specialty pharmaceutical company, Dava Pharmaceuticals Inc.